---
title: "GSK supply chain chief Simard sells GBP 774,440 of shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294393615.md"
description: "GSK supply chain chief Regis Simard sold 38,000 ordinary shares at £20.38 each on the London Stock Exchange, totaling GBP 774,440."
datetime: "2026-07-30T16:26:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294393615.md)
  - [en](https://longbridge.com/en/news/294393615.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294393615.md)
generator: "portal-rs"
---

# GSK supply chain chief Simard sells GBP 774,440 of shares

-   GSK executive Regis Simard sold 38,000 ordinary shares at £20.38 each on the London Stock Exchange. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001654954-26-007005), on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [GSK.US](https://longbridge.com/en/quote/GSK.US.md)
- [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md)
- [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md)

## Related News & Research

- [GSK: Hold Rating Reaffirmed as Near-Term Strength Offsets Long-Term Uncertainties; 2,350p Price Target Maintained](https://longbridge.com/en/news/294183934.md)
- [Bernstein Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)](https://longbridge.com/en/news/294085968.md)
- [Man Group PLC : Form 8.3 - Senior plc](https://longbridge.com/en/news/296598007.md)
- [REG - Nationwide B.S. Nationwide BS- 34VG - Results RNS - Re-sale of CCDS](https://longbridge.com/en/news/296240068.md)
- [GSK now expects 20+ phase III trial starts in 2026, up from 10](https://longbridge.com/en/news/294056670.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**